Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: Demonstrating the potential value of comprehensive real world data

Abstract

Background/Aim: The complexity and cost of treating cancer patients is escalating rapidly and increasingly difficult decisions are being made regarding which interventions provide value for money. BioGrid Australia supports collection and analysis of comprehensive treatment and outcome data across multiple sites. Here, we use preliminary data regarding the National Bowel Cancer Screening Program (NBCSP) and stage-specific treatment costs for colorectal cancer (CRC) to demonstrate the potential value of real world data for cost-effectiveness analyses (CEA). Methods: Data regarding the impact of NBCSP on stage at diagnosis were combined with stage-specific CRC treatment costs and existing lite..